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The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious
delivery systems able to deliver therapeutic genes selectively to tumors by intravenous administration. We
investigate if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are
overexpressed on numerous cancers, could result in a selective gene delivery to tumors after intravenous
administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the
targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer.
The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene
expression mainly in the tumors. Consequently, the intravenous administration of the delivery system
complexed to a therapeutic DNA led to a rapid and sustained tumor regression over one month, with long-
term survival of 100% of the animals (90% complete response, 10% partial response).The treatment was well
tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine may thus
be a promising gene delivery system for cancer therapy.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
The possibility of using genes as medicines to treat cancer is
currently limited by the lack of safe and efficacious delivery systems
able to deliver therapeutic genes selectively to tumors by intravenous
administration, without secondary effects to healthy tissues [1].
With the long-term aimof developing an efficacious cancer-targeted
gene medicine, we have recently demonstrated that systemically
administered generation 3-diaminobutyric polypropylenimine dendri-
mer (DAB) combined with Tumor Necrosis Factor (TNFα) expression
plasmid driven by a tumor-specific promoter, leads to tumor regression
in a number of murine models, with excellent long-term response [2].
Although the expression of the therapeutic genes was tumor-specific,
this gene delivery system was widely distributed in the body, which
may have reduced the therapeutic potential of this system.
In order to further improve the tumor delivery capability of this
system, we hypothesize that the conjugation of DAB dendrimer to the
iron-carrier transferrin, whose receptors are overexpressed on
numerous cancer cell lines [3], could result in a selective receptor-
mediated gene delivery to tumors after intravenous administration
and therefore lead to an increased therapeutic efficacy. Transferrin
has previously been used successfully as a tumor-targeting ligand for
many drug and gene delivery systems [4–9].
The objectives of this study are therefore 1) to prepare and
characterize a novel transferrin-bearing generation 3 polypropyleni-
mine dendrimer (DAB-Tf) and 2) to evaluate in vitro and in vivo the
therapeutic and targeting efficacies of this therapeutic system.
2. Materials and methods
2.1. Cell lines and reagents
Quanti-iT™ PicoGreen® dsDNA reagent and tissue culture media
were obtained from Invitrogen (Paisley, UK). Vectashield® mounting
medium with 4′,6-diamidino-2-phenylindole (DAPI) was obtained
from Vector Laboratories (Peterborough, UK). Passive lysis buffer was
purchased from Promega (Southampton, UK). Label IT® Cy3 Nucleic
Acid Labeling kit was from Cambridge Biosciences (Cambridge, UK).
N-[1-(2,3-Dioleoyloxy) propyl]-N,N,N-trimethylammonium methyl-
sulfate (DOTAP) liposomal transfection reagent was purchased from
Roche (Burgess Hill, UK). Polypropylenimine dendrimer generation
3 (PPI G3; DAB-Am16), transferrin and all other chemicals were pur-
chased from Sigma Aldrich (Poole, UK). A431 epidermoid carcinoma
and T98G glioblastoma were obtained from the European Collection
of Cell Cultures (Salisbury, UK). The expression plasmids encoding
Tumor necrosis factor (TNF)α (pORF9-mTNFα) and β-galactosidase
(pCMVsport β-galactosidase) were obtained respectively from
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InvivoGen (San Diego, CA) and Invitrogen (Paisley, UK). They were
purified using an Endotoxin-free Giga Plasmid Kit (Qiagen, Hilden,
Germany).
2.2. Synthesis and characterization of transferrin-bearing
polypropylenimine dendrimer
2.2.1. Conjugation of transferrin to DAB dendrimer
Polypropylenimine dendrimer generation 3 (DAB) was conjugated
to transferrin (Tf) by using dimethylsuberimidate (DMSI) as a cross-
linking agent in a similar manner to that reported for transferrin-
bearing vesicles [10]. Polypropylenimine dendrimer DAB (24 mg) was
added to transferrin (6 mg) and DMSI (12 mg) in triethanolamine HCl
buffer (pH 7.4, 2 mL). The coupling reaction was allowed to take place
at room temperature for 2 h whilst stirring. The final product was
purified by size exclusion chromatography using a Sephadex G75
column and freeze-dried. DAB-Tf was then dissolved in D2O at a
concentration of 5 mg/mL. The grafting of the transferrin to DAB was
assessed by 1H NMR spectroscopy, using a Jeol Oxford NMR AS 400
spectrometer.
2.2.2. Characterization of polyplex formation by PicoGreen® assay
The degree of DNA accessibility following complexationwith DAB-Tf
was assessed by PicoGreen® assay, performed according to the
supplier's protocol. The fluorescence of PicoGreen® significantly
increases on intercalation with double stranded DNA. The electrostatic
interaction between the anionic DNA and cationic group of the polymer
on formation of the Tf-bearing DAB–DNA polyplex condenses the DNA
and reduces the number of PicoGreen® binding sites, ultimately
reducing the fluorescence intensity for the PicoGreen® solution.
PicoGreen® reagent was diluted 200-fold in Tris–EDTA (TE) buffer
(10 mMTris, 1 mMEDTA, pH7.5) on the day of the experiment. OnemL
of complex polymer–DNA at various polymer:DNA weight ratios
(20:1, 10:1, 5:1, 2:1, 1:1, 0.5:1 and 0:1) was added to 1 mL PicoGreen®
solution. The DNA concentration in the cuvette (10 µg/mL) was kept
constant throughout the experiment. The fluorescence intensity of the
complexes in the presence of PicoGreen® was analyzed at various
time points with a Varian Cary Eclipse Fluorescence spectrophotometer
(λexc: 480 nm, λem: 520 nm). Resultswere represented as percentage of
DNA condensation (=100−% relative fluorescence to DNA control)
(n=4).
2.2.3. Polyplex size and zeta potential measurement
Size and zeta potential of Tf-bearing DAB complexed to DNA were
measured by photon correlation spectroscopy, using a Malvern
Zetasizer Nano series Nano-ZS (Malvern Instruments, Malvern, UK).
2.3. In vitro biological characterization
2.3.1. Cell culture
A431 and T98G cell lines overexpressing Tf receptors were grown
as monolayers in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) L-
glutamine and 0.5% (v/v) penicillin–streptomycin. Cells were cultured
at 37 °C in a 5% carbon dioxide atmosphere.
2.3.2. In vitro transfection
Transfection efficacy of the DNA carried by the transferrin-bearing
dendrimer was assessed with a plasmid coding for β-galactosidase
(pCMV βgal), using a β-galactosidase transfection assay. A431 and
T98G cells were seeded in quintuplicate at a density of 2000 cells/well
in 96-well plates. After 72 h incubation, the cells were treated with
DAB-Tf complexed to plasmid DNA encoding β-galactosidase, at the
polymer:DNA weight ratios used for the DNA condensation experi-
ment. Naked DNA served as a negative control, formulations of
DOTAP–DNA (polymer:DNA weight ratio 5:1) and DAB–DNA (poly-
mer:DNA weight ratio 5:1) served as positive controls. DNA
concentration (1 µg/well) was kept constant for all the formulations
tested. After 72 h incubation, cells were lysed with 1× passive lysis
buffer (PLB) (50 µL/well) for 20 min. The cell lysates were subse-
quently analyzed for β-galactosidase expression [11]. Briefly, 50 µL of
the assay buffer (2 mM magnesium chloride, 100 mM mercaptoetha-
nol, 1.33 mg/mL ο-nitrophenol-β-galactopyranoside, 200 mM sodium
phosphate buffer, pH 7.3) was added in each well containing
the lysates. After 2 h incubation at 37 °C, the absorbance of the sam-
ples was read at 405 nm with a plate reader (Thermo Lab Systems,
Multiscan Ascent, UK).
2.3.3. Cellular uptake
Imaging of the cellular uptake of the DNA carried by DAB-Tf was
carried out using confocal microscopy. Labeling of plasmid DNA with
the fluorescent probe Cy3 was performed using a Label IT® Cy3
Nucleic Acid Labeling kit, as described by the manufacturer. A431 and
T98G cells were grown on microscope slides (0.6×106 cells/90-mm
Petri dish) at 37 °C for 24h. The cells were then incubated for further
24 hwith Cy3-labeled DNA (6 µg/dish) complexed to DAB-Tf and DAB
at the polymer:DNA weight ratios giving their highest transfection
efficacy (DAB-Tf:DNA: 10:1; DAB:DNA: 5:1 [11]). Control slides were
treated with naked DNA or remained untreated. The slides were then
washed with PBS and fixed in methanol for 30 min. Upon staining of
the nuclei with DAPI, the cells were examined using a Leica TCS SP5
confocal microscope. DAPI was excited with the 405 nm laser line
(bandwidth: 415–491 nm), whereas Cy3 was excited with the
453 nm laser line (bandwidth: 550–620 nm).
2.3.4. In vitro anti-proliferative activity
Anti-proliferative activity of transferrin-bearing DAB complexed
with plasmid DNA encoding TNFα was assessed in A431 and T98G
cancer cell lines. Cells (2×103 cells per well in 96-well plates seeded
72h prior treatment) were incubated for 72h with the DNA formu-
lations at final concentrations of 10−3 to 10 000 µg/mL. Anti-
proliferative activity was evaluated by measurement of the growth
inhibitory concentration for 50% of the cell population (IC50) in a
standard MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide] assay. Absorbance was measured at 570 nm using a plate
reader. Dose–response curves were fitted to percentage absorbance
values to obtain IC50 values (three independent experiments with n=5
for each concentration level).
2.4. In vivo study
2.4.1. Animals
Female immunodeficient BALB/c mice were housed in groups of
five at 19 °C to 23 °C with a 12-hour light–dark cycle. They were fed a
conventional diet (Rat and Mouse Standard Expanded, B&K Universal,
Grimston, United Kingdom) with mains water ad libitum. Experimen-
tal work was carried out in accordance with UK Home Office
regulations and approved by the local ethics committee.
2.4.2. Biodistribution of gene expression
Groups of mice (n=5, initial mean weight 18 g) bearing sub-
cutaneously implanted A431 tumors overexpressing transferrin
receptors, were treated intravenously with a single injection of Tf-
bearing and control DAB dendrimers carrying β-galactosidase
expression plasmid (50 µg of DNA). Mice were sacrificed 24 h after
injection. Their organs were removed, immediately frozen in liquid
nitrogen and analyzed for their β-galactosidase levels as previously
described [12].
2.4.3. In vivo tumoricidal activity
Mice (n=5, initial mean weight 18 g) bearing well-established,
vascularized subcutaneous A431 tumors, were treated by intravenous
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injection with the Tf-bearing DAB dendrimer carrying TNFα expres-
sion plasmid, the non-targeted dendrimer carrying the same
therapeutic plasmid, the targeted dendrimer either alone or carrying
a non-therapeutic β-galactosidase expression plasmid and naked
DNA. Gene therapy treatment was administered by intravenous tail
vein injection (50 µg of DNA) once daily for ten days. Animals were
weighed daily and tumor volume was determined by caliper
measurements (volume=d3×π/6). Results were expressed as rela-
tive tumor volume (rel. Voltx=Voltx /Volt0) and responses classified
analogous to Response Evaluation Criteria in Solid Tumors (RECIST,
[13]). Progressive disease is defined as an increase in relative tumor
volume higher than 1.2-fold, stable disease as a relative volume
between 0.7 and 1.2 of starting volume, partial response as measure-
able tumor with a reduction of more than 30% (0–0.7) and complete
response as the absence of any tumor.
2.5. Statistical analysis
Results were expressed as means±standard error of the mean
(S.E.M). Statistical significance was determined by one-way analysis
of variance (ANOVA) followed by the Bonferroni multiple compar-
ison post-test (GraphPad Prism software). Differences were consid-
ered as significant when Pb0.05.
3. Results and discussion
3.1. Conjugation of transferrin to DAB dendrimer
The synthesis of DAB-Tf was confirmed by 1H NMR spectrum, as
follows (Fig. 1).
1H NMR (D2O): δDAB (H2N-CH2-CH2)=2.65; DAB (N-CH2-CH2)=
2.45; DAB (CH2-CH2-CH2)=1.64; DAB-Tf (CH2-CH2-NH-CO)=3.70;
DAB-Tf (H2N-CH2-CH2)=2.80; DAB-Tf (N-CH2-CH2)=2.55; DAB-
Tf (CH2-CH2-CH2)=1.64; DAB-Tf=2.90–2.40 (m); 2.25 (t); 1.20–
1.90 (m).
The NMR spectrum of DAB had a characteristic broad triplet peak
for the CH2 adjacent to peripheral primary amino group at δ 2.65,
which was slightly shifted to 2.80 ppm in the NMR spectrum of DAB-
Tf. However, in the 1H NMR spectrum of DAB-Tf, an additional broad
triplet at δ 3.70 was observed which is compatible to the methylene
protons adjacent to an amide unit. This indicated that some of the
peripheral amino groups had reacted with the carboxyl group of the
DMSI to form an amide linkage with transferrin. Multiple small peaks
between δ 1.30 and 3.40 corresponded to protons for transferrin.
These results demonstrated that DAB has been successfully conjugat-
ed to transferrin by cross-linking with DMSI.
1H NMR spectra showed that the dendrimer is 50% bound to
transferrin as signified by the ratio of the integrals of resonances at δ
3.70 and 2.80 for methylene units (e and a) attached to the amide-
linked transferrin and free amine, respectively.
This synthesis is a simple one-step procedure unlike the synthetic
methods previously reported, which generally involve dicyclohexylcar-
bodiimide (DCC). DCC is widely used for amide and ester formation.
However, its by-productN, N-dicyclohexyl urea can only be removed by
lengthy processes such asfiltration followed by extensive dialysis. Using
dimethylsuberimidate as a crosslinker avoids this problem.
3.2. Characterization of polyplex formation by PicoGreen® assay
The polypropylenimine dendrimer DAB can efficiently form
complexes with plasmid DNA through electrostatic interactions
between its protonated primary amines and the negatively charged
phosphodiester groups of the DNA. However, the conjugation of
transferrin may affect the dendrimer ability to complex DNA. For that
reason, we examined the influence of the conjugation of transferrin on
the dendrimer ability to form complexes with DNA, by using a
PicoGreen® assay. Transferrin-bearing DAB was able to condense
more than 70% of the DNA, independently of the weight ratio tested
(Fig. 2A). DNA condensation occurred almost instantaneously andwas
found to be stable over at least 24 h. It increased with increasing
weight ratios, reaching a plateau near 85% at a dendrimer:DNAweight
ratio of 0.5:1 and an almost complete condensation at a dendrimer:
DNA weight ratio of 20:1. These results demonstrated that complexes
can be formed through electrostatic interactions between DNA and
DAB-Tf, although an excess of dendrimer is required to ensure
efficient DNA condensation. The conjugation of transferrin to DAB did
not destabilize DNA condensation, which is a prerequisite for the
transport of this macromolecule. The formation of nanoparticles of
transferrin-bearing DAB complexed to DNAwas also demonstrated by
transmission electron microscopy (Fig. 1 in Supplementary data). A
gel retardation assay confirmed the complete and partial DNA
condensation obtained respectively for polymer:DNA weight ratios
of 10:1 and 1:1, as demonstrated by the DNA condensation
experiment (Fig. 2 in Supplementary data).
3.3. Polyplex size and zeta potential measurement
Transferrin-bearing DAB polyplex displayed a z-average mean
diameter of 287 nm (polydispersity index: 0.393). The conjugation of
transferrin to the periphery of DAB led to a slight increase of the
polyplex size compared to the unmodified DAB polyplex, which had an
average size of 196 nm (polydispersity index: 0.683). As the cut-off size
for extravasation has been found to be 400 nm formost tumors [14,15],
this delivery system has the required properties to access the tumor
cells. Zeta-potential experiments demonstrated that transferrin-bearing
Fig. 1. 1H NMR spectra of generation 3 polypropylenimine dendrimer conjugated to
transferrin (DAB-Tf) (A) (B: 1H NMR spectra of the unmodified dendrimer).
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and control DAB polyplexes were bearing a positive surface charge. The
zeta potential of DAB-Tf polyplex was 1.03 mV, smaller than that of the
unmodified DAB polyplex (6.42 mV). This decrease is most likely due to
the presence of the negatively charged amino acids of transferrin and
would lead to a minimization of the non-specific interactions of the
polyplex with the negatively charged cellular membranes [16].
3.4. In vitro transfection
Transfection efficacy was determined by quantifying the expression
of β-galactosidase encoded on the plasmid. The highest transfection
level after treatment with DAB-Tf at various dendrimer:DNA ratios was
obtained at a DAB-Tf:DNA weight ratio of 10:1 on T98G (Fig. 2B) and
A431 cells (Fig. 2C). The conjugation of Tf to DAB led to an improved
transfection compared to the unmodified DAB and DOTAP on both the
tested cell lines. On T98G cells, gene expression following treatment
with DAB-Tf (12.27.10−3±0.27.10−3 U/mL)was 1.3 times higher than
that of unmodifiedDABpolyplex (9.05.10−3±0.25.10−3 U/mL) and2.8
times higher than that of DOTAP–DNA (4.38.10−3±0.21.10−3 U/mL).
On A431 cells, gene expression following treatment with DAB-Tf
polyplex (11.07.10−3±0.37.10−3 U/mL) was 2.2 times higher than
that of unmodified DAB polyplex (5.07.10−3±0.21.10−3 U/mL) and 3
times higher than that of DOTAP–DNA (3.67.10−3±0.16.10−3 U/mL).
No gene expression was observed after treatment with control DNA, as
expected.
The improved β-gal expression induced by Tf-bearing DAB com-
pared to unmodified DAB most likely resulted from the transferrin-
specific uptake by the cancer cells overexpressing Tf receptors. The
higher zeta potential of the DAB polyplex would have otherwise
resulted in a higher transfection efficacy of the unmodified dendrimer,
due to the strong correlation between cellular uptake and positive
charge density of polyplexes [16]. This improved β-gal expressionwas
in accordance with that observed with other Tf-bearing gene delivery
systems [17,18].
Fig. 2. In vitro quantitative characterization of DAB-Tf polyplex: A) DNA condensation of
DAB-Tf polyplex using PicoGreen® reagent at various durations and polymer:DNA weight
ratios: 20:1 (■), 10:1 (●), 5:1 (▲), 2:1 (▼), 1:1 (♦), 0.5:1 (◄) andDNAonly (►). Results are
expressed asmean±SEM (n=4). B, C) Transfection efficacy of DAB-Tf polyplex at various
polymer:DNAweight ratios relative to DOTAP–DNA and native DAB–DNA in T98G (B) and
A431 cells (C). DOTAP–DNA and DAB–DNA were dosed at their optimal carrier:DNA ratio
of 5:1 (n=15). ⁎: Pb0.05 vs the highest transfection treatment.
Fig. 3. Confocal microscopy imaging of the cellular uptake of Cy3-labeled DNA (6 µg/
dish) either complexed with DAB-Tf (A, B), DAB (C, D) or free in solution (E, F) after
incubation for 24h with T98G (left) and A431 cells (right). Blue: nuclei stained with
DAPI (excitation: 405 nm laser line, bandwidth: 415–491 nm), green: Cy3-labeled DNA
(excitation: 453 nm laser line, bandwidth: 550–620 nm) (Magnification: ×40).
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3.5. Cellular uptake
The uptake of Cy3-labeled DNA by A431 and T98G cells was
qualitatively confirmed using confocal microscopy (Fig. 3). Co-
localization of DNA in the nuclei was clearly visible in both cell lines
treated with Tf-bearing DAB polyplex, as well as in A431 cells after
treatment with DAB polyplex. It was however much weaker after
treatment with DAB polyplex in T98G cells. Cy3-labeled DNA was also
disseminated in the cytoplasm after treatment with targeted and non-
targeted formulations in both cell lines. By contrast, cells treated with
free DNA did not show any Cy3-derived fluorescence. The grafting of
Tf to DAB therefore seems to improve DNA uptake by T98G cells, but
has little influence on A431 cell line, for which the nuclear uptake of
DNA seems to be similar after treatment with both targeted and non-
targeted dendrimers.
3.6. In vitro anti-proliferative activity
The conjugation of transferrin toDAB led to an increase of the in vitro
anti-proliferative activity compared to the unmodified polyplex (IC50 of
7.09±0.88 µg/mL and 9.47±1.15 µg/mL respectively for the targeted
polyplex and for the non-targeted polyplex in A431 cells, 21.72±
2.68 µg/mL and 29.84±2.79 µg/mL respectively for the targeted
polyplex and for the non-targeted polyplex in T98G cells). DNA alone
didnot exert any cytotoxicity to the cells, thus emphasizing theneedof a
gene delivery system for the delivery of therapeutic DNA to cancer cells.
These results may be attributed to the improved transfection efficacy
when treated with Tf-bearing DAB polyplex. Although the improved
transfection levels after treatment with Tf-bearing DAB polyplex at a
polymer:DNA ratio of 10:1 were very close for the two cell lines, the
anti-proliferative activity was more pronounced on A431 than on T98G
cells, probably due to different sensitivities of the cell lines toward
TNFα-mediated apoptosis.
3.7. Biodistribution of gene expression
The intravenous administration of control DAB polyplex resulted in
gene expression mainly in the liver (42.4±8.7 mU β-galactosidase per
organ) followed by the tumor to a lesser extent (25.8±5.6 mU β-
galactosidase per organ) (Fig. 4). By contrast, the grafting of transferrin
to DAB led to gene expression mostly in the tumor (38.1±1.3 mU β-
galactosidase per tumor, significantly higher than that obtained after
treatment with control DAB polyplex), with a β-galactosidase amount
4-fold higher than in the liver (8.9±1.1 mUβ-galactosidase per organ).
The β-galactosidase amounts in the other organs were dramatically
reduced (less than 4 mU β-galactosidase per organ), thus confirming
the targeting efficacy of transferrin to the tumors.
Similar improvements have been obtained by Kircheis et al. [19]
when using Tf-bearing polyethylenimine (PEI). The authors demon-
strated that Tf-bearing PEI polyplexes led to a specific expression in
the tumor, whereas expression in the lungs and the other organs was
dramatically reduced compared to the non-targeted PEI.
Transferrin receptors are expressed in a range of cancer cells, but
also on rapidly growing normal cells. The combination of active
targeting, based on the use of ligands, and passive targeting, based on
the accumulation of particulate delivery systems due to the enhanced
permeability and retention effect [20], provides a tumor-selective
targeting strategy.
3.8. In vivo tumoricidal activity
Tf-targeted DAB dendrimer complexed with TNFα plasmid induced
a tumor regression within 24h compared to untreated tumors (Fig. 5).
Fig. 4. Biodistribution of gene expression after a single intravenous administration of Tf-
bearing DAB polyplex (light grey) and non-targeted DAB polyplex (dark grey) (50 µg
DNA administered). Results were expressed as milliunits β-galactosidase per organ
(n=5). *: Pb0.05: Tf-bearing polyplex vs unmodified polyplex for each organ.
Fig. 5. A) Tumor growth studies in a well-established mouse A431 xenograft model after
intravenous administration of transferrin-bearing DAB polyplex carrying plasmid DNA
encoding TNFα (50 µg/injection) (green), non-targeted DAB polyplex (orange), uncom-
plexed DAB-Tf (dark blue), DAB-Tf polyplex carrying a non-therapeutic DNA encoding β-
galactosidase (pale blue), naked DNA (red) and untreated tumors (black). Treatment was
administered by intravenous tail vein injection once daily for ten days. Results were
expressed as relative tumor volume (rel. Voltx=Voltx/Volt0) (n=5). B) Magnification of
the above graph. C) TumorhistologyatDay 6 after treatmentwith transferrin-bearingDAB
polyplex carrying plasmid DNA encoding TNFα (left), non-targeted DAB polyplex (partial
tumor: whole tumor size: 3.5 mm×4.5 mm) (middle) and untreated tumors (partial
tumor: whole tumor size: 9 mm×10 mm) (right) (H & E staining) (bar: 1 mm).
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This treatment led to a marked tumor regression over the following
month and long-term survival of 100% of the animals. On the last day of
the experiment, 90%of the tumors treatedwith Tf-bearingDABpolyplex
had completely disappeared, while the remaining 10% showed a partial
response (Fig. 6B). Treatment with non-targeted DAB complex led to
tumor regression as well, but with a less successful outcome (40%
complete response, 60% partial response). Although the injection of free
DABdendrimer led to amarked growth retardation on the same cell line
due to the intrinsic antitumor activity of the dendrimer [2], the grafting
of transferrin to this dendrimer seems to inhibit this effect for these
experimental settings. The administration of DAB-Tf alone or carrying a
non-therapeutic DNAencodingβ-galactosidase (pale blue) led to tumor
growth. On the last day of the experiment, 100% of the tumors treated
with Tf-bearing DAB only or carrying β-galactosidase expression
plasmid, free DNA or left untreated were progressive. Histological
sections of tumors taken on Day 6 showed widespread necrosis, a
known mechanism for the antitumor effects of TNFα, after treatment
with Tf-bearing and non-targeted DAB polyplex and a pronounced
reduction of the size of the tumor after treatment with the targeted
polyplex (Fig. 5C).
As a result, the extended survival of the mice treated with targeted
DAB polyplex and unmodified DAB polyplex was 34 days compared to
untreated mice (Fig. 6C). Interestingly, treatment with DAB-Tf
uncomplexed with DNA led to an extended survival of the mice of
16 days compared to untreated animals. The treatments were well
tolerated by the mice and no apparent signs of toxicity or significant
weight loss were observed (Fig. 6A). These therapeutic effects,
together with the lack of apparent toxicity, potentially make the
transferrin-bearing polypropylenimine dendrimer an interesting gene
delivery system as part of a gene medicine.
In conclusion, novel transferrin-bearing DAB polypropylenimine
dendrimer led to an improved tumor specificity of gene expression and
sustained tumor regression after intravenous administration without
visible secondary effect to themice. Transferrin-bearingDAB dendrimer
is therefore a highly promising delivery system for cancer therapy.
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